Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization

Figure 4 Survival according to presence of sarcopenia before and after trans-arterial chemoembolization. A and B: Progression free survival (A) and overall survival (OS) (B) according to the presence or not of sarcopenia before trans-arterial chemoembolization (TACE); C: OS according to presence or not of sarcopenia after TACE; D: OS according to the presence or not of sarcopenia before TACE, and appearance of sarcopenia after TACE designated as post-TACE sarcopenia. Results were computed using the Kaplan-Meier method and compared by the log rank test. The patients at risk are represented under the x-axis.